Nemolizumab Therapeutic Cheat Sheet
Atopic dermatitis and prurigo nodularis are chronic, life-altering diseases with a common feature of debilitating pruritus that significantly impacts our patients’ qualities of life. For those with resistant and extensive disease, dermatologists now have nemolizumab in our armamentarium, the first FDA approved IL-31 inhibitor. We continue our series, Therapeutic Cheat Sheet, with a closer look a …
Atopic dermatitis and prurigo nodularis are chronic, life-altering diseases with a common feature of debilitating pruritus that significantly impacts our patients’ qualities of life. For those with resistant and extensive disease, dermatologists now have nemolizumab in our armamentarium, the first FDA approved IL-31 inhibitor. We continue our series, Therapeutic Cheat Sheet, with a closer look a … 
Atopic dermatitis is a common, chronic, life-altering disease. With its visibility and debilitating pruritus, atopic dermatitis significantly impacts our patients’ quality of life. For those with resistant and extensive disease, we are happy to have numerous new systemic agents at our disposal, one being tralokinumab, an IL-13 antagonist. We continue our series, Therapeutic Cheat Sheet, with a c … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. Adam Friedman (Professor and Chair of Dermatology who serves as Associate Residency Program Director, Director of Translational Research, and Director of the Supportive Oncodermatology Program in the GW Department of Dermatology) about the latest in Atopic Dermatitis (AD). Watch as he discu … 
Atopic dermatitis (AD) is a common skin condition characterized by pruritus and occurs as a result of factors related to impaired skin barrier and immune response, as well as environmental and infectious agents. Patients with poor control on topical therapy are looking for safe and effective systemic treatments. We continue our series, Therapeutic Cheat Sheet, with a closer look at dupilumab, whic … 
To kick off ODAC 2021, Dr. Yasmine Kirkorian, MD, tackled two clinical dilemmas that are frequently seen among pediatric patients in the dermatology office: poorly controlled atopic dermatitis and infantile hemangiomas. Dr. Kirkorian reviewed currently available systemic therapies for atopic dermatitis as well those in the drug development pipeline. She went into detail about how she utilizes he …